Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
- Conditions
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Gaetano Ciancio
- Target Recruit Count
- 32
- Registration Number
- NCT01680861
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 74
- Registration Number
- NCT01678664
- Locations
- 🇫🇷
Hôpital Trousseau, Tours, France
🇫🇷Hôpital Avicenne, Bobigny, France
🇫🇷Hôpital Côte de Nacre, Caen, France
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01677390
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Rocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1939
- Registration Number
- NCT01674140
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
- Conditions
- Interventions
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 821
- Registration Number
- NCT01668784
- Locations
- 🇫🇷
Local Institution - 0006, Vandoeuvre-lès-Nancy, Lorraine, France
🇮🇹Local Institution - 0102, Rozzano, Italy
🇫🇷Local Institution - 0007, Lyon Cedex, France
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 56
- Registration Number
- NCT01665768
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2012-08-13
- Lead Sponsor
- MARIO ABBUD FILHO
- Target Recruit Count
- 80
- Registration Number
- NCT01663805
- Locations
- 🇧🇷
Instituto de Urologia e Nefrologia, São José do Rio PReto, São Paulo, Brazil
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2019-03-06
- Target Recruit Count
- 25
- Registration Number
- NCT01661283
- Locations
- 🇺🇸
Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hospital do Rim e Hipertensão
- Target Recruit Count
- 47
- Registration Number
- NCT01653041
- Locations
- 🇧🇷
Hospital do Rim e Hipertensão, São Paulo, Brazil
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 25
- Registration Number
- NCT01648465
- Locations
- 🇬🇷
Dept of Medical Oncology, 251 General Airforce Hospital, Athens, Greece
🇬🇷2nd Dept of Internal Medicine, Propaedeutic, University Hospital "Attikon", Athens, Greece
🇬🇷Division of Oncology, Dept of Internal Medicine, University Hospital of Patras, Patra, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.